Investor Presentaiton

SAR-bisPSMA diagnostics Two Phase III trials required for registration in prostate cancer: one in the pre-definitive treatment and one in the biochemical recurrence (BCR) setting. Clarity is expecting to commence these registrational trials in 2023. PROPELLER PROPELLER: PET Imaging of participants with confirmed prostate cancer Compares 64CU SAR-bisPSMA to 68Ga PSMA-11 (Approved in the US and Australia) in participants with untreated prostate cancer who are planned for radical prostatectomy Trial design Phase I multi-centre, blinded review, dose ranging, non-randomised study in 30 patients across Australia. | COBRA COBRA: Copper-64 SAR-bisPSMA in BCR prostate cancer Investigates the safety and tolerability of 64CU-SAR-bisPSMA as well as its ability to correctly detect recurrence of prostate cancer in participants with BCR of prostate cancer following definitive therapy Trial design Phase I/II multi-centre, single arm, non-randomised study in up to 50 patients across the US Status Screening + 68Ga PSMA-11 scan Assignment to dosing cohorts 1-3 64CU SAR- bisPSMA scan Reached 50% recruitment in December 2021 Next milestones Recruitment complete in Q2 2022 Topline data in Q4 2022 CLARITY 2014 M Status Suspected Assessed BCR based on PSA, negative on 64CU SAR- bisPSMA against composite conventional imaging scan (@~1h & 24h) reference standard First patient dosed in April 2022, recruitment ongoing Next milestone • 50% recruitment in Q3 2022 PROPELLER clinicaltrials.gov identifier: (NCT04839367) COBRA clinicaltrials.gov identifier: (NCT05249127) 15

View entire presentation